Cantor Fitzgerald maintains Vertex stock Overweight rating
Investors are keeping a close eye on Vertex as the PDUFA date approaches, with the potential approval of suzetrigine marking ...
Zacks.com on MSN21h
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...
STAT1d
Tris Pharma, looking to compete with Vertex, reports acute pain trial success
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...